A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis

The Journal of Biological Chemistry
Sylvia LucknerCaroline Kisker


InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for the development of novel drugs against tuberculosis, a disease that kills more than two million people each year. InhA is the target of the current first line drug isoniazid for the treatment of tuberculosis infections. Compounds that directly target InhA and do not require activation by the mycobacterial catalase-peroxidase KatG are promising candidates for treating infections caused by isoniazid-resistant strains. Previously we reported the synthesis of several diphenyl ethers with nanomolar affinity for InhA. However, these compounds are rapid reversible inhibitors of the enzyme, and based on the knowledge that long drug target residence times are an important factor for in vivo drug activity, we set out to generate a slow onset inhibitor of InhA using structure-based drug design. 2-(o-Tolyloxy)-5-hexylphenol (PT70) is a slow, tight binding inhibitor of InhA with a K(1) value of 22 pm. PT70 binds preferentially to the InhA x NAD(+) complex and has a residence time of 24 min on the target, which is 14,000 times longer than that of the rapid reversible inhibitor from which it is derived. The 1.8 A crystal structure of the ternary complex be...Continue Reading


Jun 12, 1979·Biochemistry·J W WilliamsR G Duggleby
Aug 26, 1998·Nature·L M McMurryS B Levy
Nov 26, 1998·Progress in Lipid Research·C E BarryY Yuan
Jul 5, 2003·The Journal of Biological Chemistry·Andrzej LewandowiczVern L Schramm
Nov 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Richa RawatPeter J Tonge
Jun 25, 2004·Nucleic Acids Research·Matthias Heinig, Dmitrij Frishman
May 1, 1997·Acta Crystallographica. Section D, Biological Crystallography·G N MurshudovE J Dodson
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Aug 5, 2006·Nature Reviews. Drug Discovery·Robert A CopelandThomas D Meek
Aug 15, 2006·Nature Medicine·Catherine VilchèzeWilliam R Jacobs
Apr 25, 2007·Nucleic Acids Research·Ian W DavisDavid C Richardson
Jan 16, 2008·Accounts of Chemical Research·Hao Lu, Peter J Tonge
Apr 17, 2008·Biochemistry·Peter J Tummino, Robert A Copeland
May 7, 2008·Bioorganic & Medicinal Chemistry Letters·Christopher W am EndePeter J Tonge
May 16, 2008·FEMS Immunology and Medical Microbiology·Amita Jain, Rajesh Mondal
Aug 1, 2007·Journal of Applied Crystallography·Airlie J McCoyRandy J Read

❮ Previous
Next ❯


Apr 23, 2013·Journal of Chemical Information and Modeling·Tomohiro KinjoShunsuke Aoki
Jul 31, 2013·Journal of Chemical Information and Modeling·Ivani PauliOsmar Norberto de Souza
Jun 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sarah A StanleyDeborah T Hung
Oct 30, 2012·Bioinformatics·Benjamin MergetChristoph A Sotriffer
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Nina LiuPeter J Tonge
Jun 2, 2011·Antimicrobial Agents and Chemotherapy·Catherine VilchèzeWilliam R Jacobs
Dec 3, 2013·Nature Chemical Biology·Ruben C HartkoornStewart T Cole
Oct 13, 2015·International Journal of Molecular Sciences·Camilo Henrique da Silva LimaMagaly Girão Albuquerque
Nov 11, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Ondrej HolasMartin Dolezal
Dec 19, 2015·Nature Reviews. Drug Discovery·Robert A Copeland
Mar 5, 2013·Drug Discovery Today·Albert C PanDavid E Shaw
Apr 10, 2012·European Journal of Medicinal Chemistry·Christophe MenendezMichel Baltas
Jan 31, 2015·Journal of Chemical Information and Modeling·Alexander L PerrymanArthur J Olson
Jun 16, 2011·Proteomics·Matthias T Ehebauer, Matthias Wilmanns
Jan 11, 2014·Protein Science : a Publication of the Protein Society·Ling JiangYuhui Dong
May 22, 2016·Journal of Biomolecular Structure & Dynamics·Vivek Kumar, M Elizabeth Sobhia
Jul 12, 2016·Expert Opinion on Therapeutic Patents·Jan Zitko, Martin Doležal
Sep 25, 2016·Drug Discovery Today·Kaja RožmanLourdes Encinas
Jul 6, 2015·European Journal of Medicinal Chemistry·Aurélien CholletMichel Baltas
Jun 10, 2017·Medicinal Research Reviews·Vajinder KumarRahul Jain
Jun 24, 2017·ACS Chemical Neuroscience·Peter J Tonge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.